The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. For GENEDX HOLDINGS, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Most Powerful Force Impacti ...

Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industryleading exome and genome tests ...

With more than 20 years of experience leading the industry in diagnosing children with rare diseases, including performing more than 80% of clinical exomes in the US today, GeneDx is increasing its focus to a rapidly growing segment of its business. GeneDx has seen an 80% year over year increase of its rapid testing business, and the payor landscape is rapidly evolving, with 11 states now offering Medicaid coverage and an increasing number of commercial payors adopting coverage policies for this critical te ...

-- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- Foundation of Clinical Collaborations to Improve Patient Care With more than 600,000 clinical exomes and genomes sequenced and over 100,000 mitochondrial genomes GeneDx has built one of the largest and most sophisticated proprietary genomic datasets. This industry leading dataset enables GeneDx to deliver more definitive answers and clinically actionable results faster to help ...

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry- leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on ...

GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Mark Massaro - BTIG, LLC Matthew Sykes - Goldman Sachs Matthew Stanton - Jefferies Group LLC Operator Ladies and gentlemen, thank you for standing by, and welcome to the GeneDx First Quarter 2024 Earni ...

GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $2.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 51.47%. A quarter ago, it was expected that this company would post a loss of $0.60 per share when it actually produced a loss of $0.59, delivering a surprise of 1.67%.Over the last four quarters, the company has surp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission file number 001-39482 GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Delaware 85-1966622 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 333 Ludlow Street, North Tower; 6th Floor Stamford, Connecticut ...

Exhibit 99.1 GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations of $61.5M with 96% year-over-year growth of exome and genome test revenue 1 Expanded first quarter 2024 adjusted gross margins from continuing operations to 61% 2 Narrowed first quarter 2024 adjusted net loss to $8.5M and delivered 71% year-over-year cash burn reduction 2 Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate pat ...

Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, C ...